Christopher S. writes, "I was wondering if you were going to put out your Best of ASCO review? I enjoyed reading it last year! In particular, how about your thoughts on the up-and-comers like Human Genome Sciences ( HGSI), Poniard Pharmaceuticals ( PARD), Cell Therapeutics ( CTIC), Peregrine Pharmaceuticals ( PPHM), etc. Do any of those dogs like they are on the right path?"
Gordon G. chimes in, "I don't have the exact date, but the PDUFA
I'm still getting a lot of email about Cell Therapeutics, including this message from Paul A. "I'm not really understanding why you continue to beat the drum on Cell Therapeutics? Aren't there more interesting stories out there? It is beginning to look very much like a vendetta rather than reporting. In all honestly, I think you've been a straight-up guy and I enjoy your work, but I think this horse has been flogged plenty, no?" On a related not, Golden Minnow asks, "Do you hate Cell Therapeutics?" Paul A. has a valid criticism. I'm not trying to pile on Cell Therapeutics, I try to write columns and stories when news happens or when I uncover information I think is important for readers and investors to have.
John C. writes, "As a practicing physician and an investor, I have been anxiously awaiting the FDA's decision for Cardiome's ( CRME) atrial fibrillation medication. Is it unusual for them to take so long? This is potentially a very useful drug and all that I have read about it makes me think it is safe and effective. I don't understand the FDA's seeming reluctance to give it approval."